Study Investigates Immune Signature as Prognostic Tool for Early-Stage Lung Cancer

Background on Lung Cancer

A recent study aimed to determine if an immune signature could serve as a reliable prognostic marker for patients diagnosed with early-stage lung cancer. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is the leading cause of cancer-related deaths globally. Many patients with early-stage lung cancer do not receive additional systemic treatment after local therapy due to insufficient evidence that chemotherapy significantly improves survival rates relative to its associated risks. Consequently, a dependable prognostic biomarker would be crucial for effective lung cancer management.

Significance of the Study

The U.S. study published in JAMA Oncology underscores the importance of identifying patients at risk for cancer recurrence, which can lead to mortality. These individuals may require further therapeutic interventions. Previous research has indicated that gene expression-based signatures could stratify survival rates among NSCLC patients. Certain gene expressions may dictate the immune system’s response, influencing tumor growth or treatment efficacy, thus potentially offering a reliable prognosis.

Challenges in Clinical Application

Despite the theoretical benefits of using gene expression signatures, they have yet to be integrated into clinical practice due to challenges such as insufficient validation of these methodologies.

Study Findings

Analysis of Tumor Tissue Samples

The study analyzed tumor tissue samples from 2,414 patients and identified an immune signature consisting of 25 gene pairs that effectively categorized patients into low and high-risk groups concerning overall survival across different tumor stages. Even after surgical resection, patients with early-stage NSCLC remain susceptible to cancer recurrence and death. However, the discussion surrounding the use of additional therapies for these patients remains contentious due to a lack of conclusive evidence.

Call for Reliable Biomarkers

The authors emphasize the urgent need for a reliable biomarker to provide accurate prognostic information, enabling the identification of patients who may benefit from additional treatment in the early disease stages.

Conclusion and Future Directions

The authors conclude that the immune-related gene pair signature could serve as a valuable prognostic biomarker for NSCLC in its early stages. Further research is necessary to assess the accuracy and reliability of this prognostic tool and to explore its clinical relevance in managing NSCLC.

Written by Jade Marie Evans, MPharm, Medical Writer

Reference: Bailiang Li et al. (2017). Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer. Available: http://jamanetwork.com. Last accessed 17th Jul 2017.